THE DEVELOPMENT OF ANTIMICROBIAL STEWARDSHIP IN THE UK: EARLY DAYS AND DRIVERS
In the early part of this century, the UK government focused heavily on reducing the incidence of healthcare-associated infections (HCAIs) [1, 2] , such as methicillin-resistant Staphylococcus aureus (MRSA) bacteremias and Clostridium difficile infections (CDI). A combination of voluntary, followed by mandatory, reporting of these infections allowed the National Health Service (NHS) to identify and monitor the scale of the problem, and then to develop actions to improve outcomes [3] . The peak incidence of MRSA bacteremias was seen in 2003, at 7700 cases, and for CDI the peak was seen in 2007, with 57,247 cases reported [4] . In response to these high levels, NHS hospital Trusts were set targets Initiative, complete with £12 million of funding for hospital pharmacies, aimed at improving the monitoring and control of anti-infectives [7] , with a view to contributing to the efforts to tackle HCAIs. This thrust pharmacists into a key role in AMS with the majority of this money being spent creating antimicrobial pharmacist positions [8] .
Immediate outcomes from this initiative were widespread update and revision of local antimicrobial guidelines, increasing interaction between Microbiology/Infectious Diseases and Pharmacy (leading to development of, or more frequent, joint ward rounds), and a dramatic increase in the provision of education and training to healthcare professionals in prudent antimicrobial use [8, 9] . These interventions have been associated with improved antimicrobial usage, reductions in length of stay, and improved clinical outcomes (such as reductions in CDI) [10] [11] [12] [13] [14] , and both of the high-level objectives for MRSA bacteremias and CDI cases were met with 57% and 41% In Scotland, similar targets, but without financial penalties, were set for the reduction of S. aureus bacteremia and CDI [21] which have resulted in similar significant reductions to those seen in England [22] . The national stewardship program led by Scottish Antimicrobial Prescribing Group (SAPG) has brought about reduced use of antibiotics associated with a high risk of CDI and this is acknowledged as a major factor in reducing the CDI rate [23] .
MORE RECENT DEVELOPMENTS IN UK STEWARDSHIP GUIDELINES AND STRATEGY
To better develop and standardise the stewardship strategy, official guidance and toolkits have recently been issued in the UK for community (primary) care in 2012 [24] and hospital (secondary) care, firstly in 2011 and very recently updated in 2015 [25, 26] .
In 2013, a cross-government five-year antimicrobial resistance (AMR) strategy was published which takes a 'One Health' approach to tackling AMR [27] . This outlined seven key areas for action ( Table 1 ) and recommended that, for the first time, an implementation plan and yearly progress reports be published. As healthcare in the UK is devolved into four different national services (England, Scotland, Wales and Northern Ireland) each nation has a committee, which oversees stewardship (Table 2 ). These groups are largely responsible for ensuring progress toward the AMR strategy and all have significant pharmacist input.
To date, antimicrobial pharmacists have had most involvement in three of the key areas highlighted in the UK AMR strategy, which are discussed in detail below. Antimicrobial pharmacists have a smaller role in infection prevention and control by providing pharmaceutical expertise to infection control committees and infection prevention and control teams. Also, increasing work is being carried out to improve the evidence base through research into stewardship and to strengthen UK and international collaboration.
Developing new compounds or vaccines for use in clinical practice, and the introduction of other diagnostics and treatments is usually beyond the remit of their work.
Better Access To, and Use of, Surveillance Data
Feedback of consumption data is a key element of an AMS program [28] . In order to engage prescribers, data are needed [29] and lack of it is a barrier to effective implementation of AMS [30, 31] . In the UK, consumption data have been available since 1991 for community prescribers. It is captured as part of the reimbursement of community pharmacists for dispensing NHS prescriptions [32] , but will not include antibiotics supplied by any other specific therapeutic group by taking into account the types of people who will be receiving that treatment [33] . These data can be used to drive improvements in antimicrobial prescribing rates, total antibiotic consumption and broad-spectrum antibiotic consumption (cephalosporins, fluoroquinolones and amoxicillin/clavulanate) [34, 35] . [84] proposed that total antimicrobial consumption should reduce to 2010 levels in the community [36, 37] The ESPAUR report [41] showed an increase in overall antibiotic consumption in hospital inpatients of 11.9% over the 4-year period (an average year-on-year increase of 3.5%, equivalent to 2.3-2.5 DDD per 1000 inhabitants per day). The data were reported at area level only, so did not allow benchmarking between hospitals.
ARHAI in England also proposed (although these proposals may be subject to further refinement) that total antibiotic consumption be reduced by 1% per annum over 2015-2019 (as measured by DDD per 1000 admissions per year), and total carbapenem consumption be reduced to 2010 consumption levels (as measured by the same method), corresponding to an average reduction of 20-25% [36, 37] .
Again, there has been no explicit linkage between increasing antimicrobial consumption and increasing AMR, but the ESPAUR report does show increases in both elements over the reporting period, and controlling antimicrobial consumption is recognized as a key element of the AMR strategy [41] . In 2015-2016, consumption data are being validated by hospitals as part of the Quality Premium [38] . In addition, 65% of NHS hospitals are also using a specific software package (Rx-Info Define) to benchmark hospital medicines consumption [44] . [47] provides data on primary care antibiotic prescribing with the national AMR dataset currently being developed.
Optimizing Prescribing Practice
There are two national AMS toolkits for England:
Start Smart then Focus for hospital care [25, 26] and the Treat Antibiotics Responsibly, Guidance, Education, Tools (TARGET) Antibiotics toolkit for community care [24] . Wales [48] and Monitoring and feedback of trends in antimicrobial prescribing, formulary and guideline adherence to clinical teams, and inputting into governance structures within organization. Point prevalence surveys of antimicrobial use, conducted at least annually, are widespread in the UK, though an increasing number of hospitals are using rapid feedback of quality indicator measures to drive improvements in antimicrobial prescribing [14] Managing entry of new antimicrobials onto hospital formularies, including critical review of new agents and their place in therapy Clinical research, both in support of drug registration studies, and in novel research to consolidate the evidence base around antimicrobial stewardship this activity is the well-established linkage between AMS pharmacists and their microbiologist/infectious diseases colleagues, which allows both specialties to share and contribute to optimizing patient care. Also, due to the patient load and their other responsibilities, antimicrobial pharmacists in the UK rely heavily on contributions from their hospital pharmacy colleagues to deliver the fundamentals of AMS (following appropriate education and training from the specialist pharmacists themselves), and also to identify patients that require more specialist input. However, although these activities are well-described, good-quality evidence of their impact on optimizing antimicrobial therapy and patient outcomes is sadly lacking.
Improving this evidence-base forms one of the future aspirations of the specialty, utilizing upcoming developments in data capture to take this forward (see below).
In comparison to the hospital sector, there are very few dedicated antimicrobial specialist pharmacist roles in primary care in the UK. A survey carried out in 2014 identified that, in 66% of primary care organizations, AMS roles were led by generalist prescribing advisors/ medicine management pharmacists [63] . AMS activities of pharmacists in primary care are similar to those in secondary care in respect to guideline writing, audit, education, monitoring and feedback; often teams link with hospital microbiology laboratories for clinical infection advice. Given that over 85% of antimicrobials are prescribed outside the hospital sector in the UK [41] , and with the increasing emphasis on a 'One Health' approach to tackling AMR [27] , cross-sector AMS programs, where primary and 
THE CHANGING HEALTHCARE LANDSCAPE: AN OPPORTUNITY FOR ANTIMICROBIAL PHARMACISTS?
Creating national infrastructures and technologies to help support AMS development has been important for UK antimicrobial pharmacists and their teams.
The tools already discussed have provided opportunities particularly at a local level for teams to review, develop, implement and encourage AMS strategies. However, the challenge is how to adapt local stewardship programs to the evolving, changing healthcare landscape that is the NHS. Below, are a few scenarios of where UK pharmacists are becoming involved in more novel stewardship activities.
Electronic Systems
Although there is an extensive literature on the positive contribution that electronic systems (such as computerized clinical decision support, computerized physician order entry or full EP) can provide to AMS, the bulk of this originates from the USA, South East Asia, and Australia, where such systems have been in use for many years [64] [65] [66] [67] [68] . EP is not yet widely implemented in the UK, although a handful of pathfinder hospitals have had experience with EP systems for a considerable time [69] . Furthermore, although the potential benefits from introduction of EP have long been recognized [70, 71] , little work has so far been published on the actual impact of these systems on antimicrobial usage and resistance. Four small case studies have reported on the impact of electronic systems in AMS in the UK [72] [73] [74] [75] demonstrating decreased levels of antimicrobial usage [72] , increased identification of patients requiring intervention [73] , avoidance of clinically significant drug interactions [74] and improvements in documentation of key antimicrobial indicators (such as indication and duration, which feature in the Start Smart, Then Focus toolkit) [75] .
Around 15 different providers of EP systems are active within the UK market, and these products are being used in about 20% of NHS Trusts, with an expectation that 40-50% of Trusts will have a plan for implementation of EP in place by 2016 [76] . With this large number of different solutions and timelines for implementation, there will inevitably be significant variation in how EP is used to support AMS. There is an on-going research program investigating how EP is introduced into NHS Trusts which will include work looking at effectiveness (primarily safety considerations around drug-drug interactions or allergy awareness) and outcomes [76] One such program [77] has suggested savings of approximately £180,000 over a 12-month period by rationalizing and reviewing therapies, while another two programs [77, 78] found stepping down and stopping unnecessary empiric therapy was common. 
